Basaran D, Boerner T, Suhner J, et al. - Researchers aimed at ascertaining the incidence of venous thromboembolism (VTE) among patients receiving neoadjuvant chemotherapy (NACT) for ovarian cancer (OC). In addition, they investigated the clinical risk factors linked with the development of new-onset VTE. From an institutional ovarian cancer database, they identified a total of 290 OC patients receiving NACT during the study period. Observations revealed the overall risk of > 25% for venous thromboembolism (VTE) in these OC patients. The rate was highest at initial presentation and during the induction of NACT. The only risk factor linked with an elevated risk for VTE was FIGO stage IV disease. They recommend considering prophylactic anticoagulation in OC patients receiving NACT, especially those with metastatic disease.